Moderna President Stephen Hoge Reports Sale of $17.01 Million in Common Shares

By Public Technologies
  • Moderna President Stephen Hoge sold 78,369 common shares on October 14-15, 2026, according to a beneficial ownership filing.
  • October 14 sales comprised 38,774 shares at $213.47 per share and 450 shares at $214.15.
  • The October 15 sale totaled 39,145 shares at $220.72 per share.
  • Hoge exercised stock options for 152,905 common shares at $12.21 per share over the two days.
  • His direct common stock holdings stood at 1,636,565 shares following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-26-000187), on October 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.